Aurinia Responds to Now Retracted LinkedIn Post

Core Viewpoint - Aurinia Pharmaceuticals has issued a response to a now retracted LinkedIn post that may have implications for its public image and investor confidence [1] Group 1 - The company is addressing concerns raised by the retracted post, which could affect its reputation in the market [1] - The retraction of the post indicates potential misinformation that could mislead stakeholders [1] - Aurinia emphasizes its commitment to transparency and accurate communication with investors and the public [1]